SynthesisMedicine2021
Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis.
Synthesis in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis.The oncologist · 2024Pooled it
- Aspirin versus placebo on estrogen levels in postmenopausal women: a double-blind randomized controlled clinical trial.BMC pharmacology & toxicology · 2022Trial
- Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort.Cancer reports (Hoboken, N.J.) · 2025Article
- Neutrophil extracellular traps in cancer: From mechanisms to treatments.Clinical and translational medicine · 2025Review
- Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways.ACS pharmacology & translational science · 2024Review
- Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients.Scientific reports · 2024Article
- Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence.Cureus · 2024Review
- The role of aspirin in preventing gastrointestinal cancers.Gastrointestinal oncology (Philadelphia, Pa.) · 2024Review
- First Generation of Antioxidant Precursors for Bioisosteric Se-NSAIDs: Design, Synthesis, and In Vitro and In Vivo Anticancer Evaluation.Antioxidants (Basel, Switzerland) · 2023Article
- Aspirin Affects MDA-MB-231 Vesicle Production and Their Capacity to Induce Fibroblasts towards a Pro-Invasive State.International journal of molecular sciences · 2023Article
- Selenium-Containing Agents Acting on Cancer-A New Hope?Pharmaceutics · 2022Review
- Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients.Scientific reports · 2022Article
- Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.Breast cancer research : BCR · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis.
methodsSearched PubMed, EMBASE, and other databases for literature on the relationship between aspirin use and breast cancer prognosis, with the deadline of October 2019. The related results of all-cause death, breast cancer-specific death, and breast cancer recurrence/metastasis were extracted to combine the effect amount. The sensitivity analysis and published bias analysis were carried out for the included data. Stata12.0 software was used to complete all statistical analysis.
resultsA total of 13 papers were included in the study, including 142,644 breast cancer patients. The results of meta-analysis showed that patients who took aspirin were associated with lower breast cancer-specific death (HR = 0.69, 95% CI = 0.61-0.76), all-cause death (HR = 0.78, 95% CI = 0.71-0.84), and risk of recurrence/metastasis (HR = 0.91, 95% CI: 0.82-1.00).
conclusionsAspirin use may improve all-cause mortality, specific mortality, and risk of recurrence/metastasis in patients with breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.